Pageviews:
Introduction
India just witnessed its largest ever overseas pharmaceutical deal. Sun Pharmaceutical Industries, the company behind medicines you probably have at home like Volini Gel or Pantocid, announced it would acquire the American company Organon for $11.75 billion. To put that number in perspective, that is roughly one lakh crore rupees changing hands in a single transaction. This deal is a perfect starting point to understand something that drives the corporate world every single day, and that is the strategy of growth through acquisition.
What Is an Acquisition
When one company buys another company outright, it is called an acquisition. The buyer pays for the target company’s products, its workforce, its existing customers, and its presence in markets around the world, all in one go. Think of it like buying a fully furnished house instead of building one room by room from scratch. Sun Pharma did not become India’s largest pharmaceutical company by waiting for growth to arrive on its own. Dilip Shanghvi, who started the company in 1983 with just two people in a factory in Vapi, Gujarat, leaned heavily on acquisitions to expand far faster than organic growth alone would have allowed. The purchase of Organon is simply the latest, and by far the biggest, chapter in that long story.
Why Companies Choose to Acquire
Building a new product from scratch, entering a new country, or developing a complex new technology takes a very long time and an enormous amount of money. Acquiring a company that already has those things is a shortcut that many businesses are willing to pay a large premium for. Sun Pharma wants access to the biosimilars market, which involves medicines for serious diseases like cancer and arthritis. Biosimilars are not the same as regular generic medicines. They require rigorous clinical testing to prove they work like the original reference drug, and building that capability from zero can take years. By buying Organon, Sun Pharma gets an existing biosimilars business immediately, along with Organon’s strong foothold in China, where the company earns over $800 million every year. China is the world’s second largest pharmaceutical market, and Sun Pharma had almost no presence there before this deal.
The Price of Ambition
The uncomfortable part of this deal is what comes with Organon. When Organon was split off from the American pharmaceutical giant Merck in 2021, it inherited $8.6 billion in debt but had only $574 million in cash on hand. Debt in a corporate context is often measured by a number called net leverage, which tells you roughly how many years of operating earnings it would take to pay off all the outstanding debt. Organon’s net leverage stood at nearly 4.5 times, which is considered very high. Sun Pharma, by contrast, had maintained an almost entirely debt-free position for years, which is rare for a company operating at its scale. After the Organon deal closes, Sun Pharma’s own leverage is expected to rise to around 2.3 times, a significant jump from its earlier cash-positive state. The real test for Dilip Shanghvi and his team will be generating enough cash from the combined business to bring that number back down, and to do it quickly enough.
The Story of Organon: A Company Looking for Direction
Organon’s journey since separating from Merck has been genuinely difficult to watch. Its best-known product, a women’s contraceptive implant called Nexplanon, started losing ground as its patents expired and cheaper generic versions flooded the market. A 2025 investigation then found that Organon had pushed excess quantities of Nexplanon to wholesalers, inflating short-term sales numbers in a way that eventually caught up with the company’s financials. Because so much of Organon’s cash was tied up in paying dividends and servicing its inherited debt, there was very little left to invest in new products or revive older ones. Revenues slipped by 3 to 4 percent in 2025 compared to the previous year, and management has already told investors that 2026 will look much the same. This is the company that Sun Pharma has decided to take on, believing that its manufacturing discipline and research capability can do for Organon what it has done for struggling assets before.
Why Turnarounds Are Part of the Strategy
Sun Pharma’s most instructive past acquisition was Ranbaxy Laboratories, which it bought for $4 billion in 2015. At the time, Ranbaxy had been banned from exporting to the United States by the American drug regulator over serious quality and data integrity failures, its revenues had collapsed, and debt had piled up. Sun Pharma spent the next three to four years fixing factories, clearing regulatory inspections, shutting inefficient plants, and refocusing the product mix toward higher-margin medicines. By the end of that process, Ranbaxy had stopped losing money, added roughly 25 percent to Sun Pharma’s total size, and helped push the Indian company into the ranks of the world’s top generics producers. There is also an older connection between the two companies in this latest deal. Sun Pharma’s psoriasis treatment Ilumya actually traces its origins back to research done inside Organon’s labs, which gives this acquisition a small but telling historical thread.
Final Thoughts
Acquisitions are one of the most powerful tools a company can use to grow quickly, but they are also among the riskiest. Every dollar spent buying another company is a dollar that cannot be returned to shareholders or used to build something new. The Sun Pharma and Organon deal is a clear example of a company accepting short-term debt and uncertainty in exchange for long-term scale, new capabilities, and access to markets it could not have entered easily on its own. Whether this $11.75 billion bet eventually pays off will depend on how well Sun Pharma manages the debt, revives Organon’s flagging products, and navigates one of the most competitive industries in the world. But if Dilip Shanghvi’s track record with Ranbaxy and his other past acquisitions is any guide, the odds of a disciplined turnaround are higher than they might appear right now.